198 related articles for article (PubMed ID: 31245935)
1. Risk of malignancy and neoplasia predicted by three molecular testing platforms in indeterminate thyroid nodules on fine-needle aspiration.
Partyka KL; Trevino K; Randolph ML; Cramer H; Wu HH
Diagn Cytopathol; 2019 Sep; 47(9):853-862. PubMed ID: 31245935
[TBL] [Abstract][Full Text] [Related]
2. Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing: A comparison of two proprietary testing platforms.
Partyka KL; Randolph ML; Lawrence KA; Cramer H; Wu HH
Diagn Cytopathol; 2018 Apr; 46(4):320-325. PubMed ID: 29446257
[TBL] [Abstract][Full Text] [Related]
3. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
[TBL] [Abstract][Full Text] [Related]
4. UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE.
Villabona CV; Mohan V; Arce KM; Diacovo J; Aggarwal A; Betancourt J; Amer H; Jose T; DeSantis P; Cabral J
Endocr Pract; 2016 Oct; 22(10):1199-1203. PubMed ID: 27409819
[TBL] [Abstract][Full Text] [Related]
5. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?
Yang SE; Sullivan PS; Zhang J; Govind R; Levin MR; Rao JY; Moatamed NA
Cancer Cytopathol; 2016 Feb; 124(2):100-9. PubMed ID: 26422098
[TBL] [Abstract][Full Text] [Related]
6. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
[TBL] [Abstract][Full Text] [Related]
7. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
[TBL] [Abstract][Full Text] [Related]
8. Molecular Testing of Atypical Thyroid Nodules with Corresponding Surgical Correlation: Five-Year Retrospective Review in Veterans Population.
Carr DM; Mastorides S; Stobaugh C; Carlton G; DeLand L; Borkowski A
Cureus; 2022 Feb; 14(2):e22536. PubMed ID: 35345739
[TBL] [Abstract][Full Text] [Related]
9. Comparison of thyroid fine needle aspiration biopsy results before and after implementation of Bethesda classification.
Ozdemir D; Bestepe N; Faki S; Kilicarslan A; Parlak O; Ersoy R; Cakir B
Cytopathology; 2017 Oct; 28(5):400-406. PubMed ID: 28727204
[TBL] [Abstract][Full Text] [Related]
10. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
[TBL] [Abstract][Full Text] [Related]
11. Low Malignancy Rates in Fine-Needle Aspiration Cytologies in a Primary Care Setting in Germany.
Eszlinger M; Ullmann M; Ruschenburg I; Böhme K; Görke F; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Paschke R
Thyroid; 2017 Nov; 27(11):1385-1392. PubMed ID: 28982301
[TBL] [Abstract][Full Text] [Related]
12. Examining the Bethesda criteria risk stratification of thyroid nodules.
Deniwar A; Hambleton C; Thethi T; Moroz K; Kandil E
Pathol Res Pract; 2015 May; 211(5):345-8. PubMed ID: 25796296
[TBL] [Abstract][Full Text] [Related]
13. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
14. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
15. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
[No Abstract] [Full Text] [Related]
16. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.
Wong KS; Angell TE; Strickland KC; Alexander EK; Cibas ES; Krane JF; Barletta JA
Thyroid; 2016 Jul; 26(7):911-5. PubMed ID: 27219469
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
Zhu QL; Faquin WC; Samir AE
AJR Am J Roentgenol; 2015 Oct; 205(4):861-5. PubMed ID: 26397337
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of the second-generation molecular tests in the assessment of indeterminate thyroid nodules: A systematic review and meta-analysis.
Lee E; Terhaar S; McDaniel L; Gorelik D; Gerhard E; Chen C; Ma Y; Joshi AS; Goodman JF; Thakkar PG
Am J Otolaryngol; 2022; 43(3):103394. PubMed ID: 35241290
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
[TBL] [Abstract][Full Text] [Related]
20. Bethesda Category III, IV, and V Thyroid Nodules: Can Nodule Size Help Predict Malignancy?
Kiernan CM; Solórzano CC
J Am Coll Surg; 2017 Jul; 225(1):77-82. PubMed ID: 28223197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
